Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Jul;73(1):23–28.

The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.

J V Melo 1, L Foroni 1, V Brito-Babapulle 1, L Luzzatto 1, D Catovsky 1
PMCID: PMC1541467  PMID: 3262465

Abstract

We have studied the capacity of peripheral blood cells from 26 chronic B cell leukaemias to proliferate continuously in culture; 72 attempts to establish cell lines were made. The cells were treated in vitro with or without stimulating agents: Epstein-Barr virus (EBV) and/or phorbol-ester (TPA) were the most frequently used. Fourteen cell lines of continuous growth were established from cells from 11 patients, but only four of these were proven to be derived from the original leukaemic cells. Only in the latter four lines were the karyotypic abnormalities and the patterns of immunoglobulin (Ig)-gene rearrangements identical to those found in the patients' leukaemic cells. On the other 10 lines, five had both kappa- and lambda-producing cells, and the remaining five, despite showing light-chain restriction, were proved to be non-leukaemic clones by comparing the Ig-gene rearrangement patterns before and after culture. Three of the four leukaemic cell lines (JVM-2, JVM-3 and JVM-13) were induced by EBV + TPA and derived from prolymphocytic leukaemia (PLL) cases; the fourth (JVM-14) originated from a case of chronic lymphocytic leukaemia (CLL) with increased percentage of prolymphocytes whose cells were stimulated in vitro with EBV. The immunophenotype of the three PLL lines is more mature than that of the original prolymphocytes, as shown by a reduction in surface-Ig and FMC7 expression, enhancement of cytoplasmic-Ig and increase in CD38- and transferrin receptor-positive cells. The cells from line JVM-14 retained the CD5-antigen, a marker of CLL. This study suggests that PLL and some CLL clones are arrested at a stage of maturation ideally suited to be triggered to continuous proliferation in culture. The presence of consistent chromosomal abnormalities in PLL may offer an alternative explanation for the greater proliferative potential of these cells in vitro.

Full text

PDF
23

Images in this article

26Fig. 1
on p.26
26Fig. 2
on p.26

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brito-Babapulle V., Pittman S., Melo J. V., Parreira L., Catovsky D. The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases. Leuk Res. 1986;10(2):131–138. doi: 10.1016/0145-2126(86)90035-4. [DOI] [PubMed] [Google Scholar]
  2. Brito-Babapulle V., Pittman S., Melo J. V., Pomfret M., Catovsky D. Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia. Hematol Pathol. 1987;1(1):27–33. [PubMed] [Google Scholar]
  3. Cleary M. L., Chao J., Warnke R., Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A. 1984 Jan;81(2):593–597. doi: 10.1073/pnas.81.2.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Diamond L., O'Brien T. G., Rovera G. Tumor promoters: effects on proliferation and differentiation of cells in culture. Life Sci. 1978 Nov 13;23(20):1979–1988. doi: 10.1016/0024-3205(78)90229-1. [DOI] [PubMed] [Google Scholar]
  5. Einhorn L., Ernberg I. Induction of EBNA precedes the first cellular S-phase after EBV-infection of human lymphocytes. Int J Cancer. 1978 Feb 15;21(2):157–160. doi: 10.1002/ijc.2910210205. [DOI] [PubMed] [Google Scholar]
  6. Foroni L., Catovsky D., Rabbitts T. H., Luzzatto L. DNA rearrangements of immunoglobulin genes correlate with phenotypic markers in B-cell malignancies. Mol Biol Med. 1984 Feb;2(1):63–79. [PubMed] [Google Scholar]
  7. Fu S. M., Chiorazzi N., Kunkel H. G. Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol Rev. 1979;48:23–44. doi: 10.1111/j.1600-065x.1979.tb00297.x. [DOI] [PubMed] [Google Scholar]
  8. Hurley J. N., Fu S. M., Kunkel H. G., McKenna G., Scharff M. D. Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis. Proc Natl Acad Sci U S A. 1978 Nov;75(11):5706–5710. doi: 10.1073/pnas.75.11.5706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Klein G., Klein E. The changing faces of EBV research. Prog Med Virol. 1984;30:87–106. [PubMed] [Google Scholar]
  10. Lemon S. M., Pagano J. S., Utsinger P. D., Sinkovics J. G. Cultured "hairy cells" infected with Epstein-Barr virus: evidence for B-lymphocyte origin. Ann Intern Med. 1979 Jan;90(1):54–55. doi: 10.7326/0003-4819-90-1-54. [DOI] [PubMed] [Google Scholar]
  11. Levitt M. L., Barry W. E., Helfrich M. K., Hecht B. K., Henderson E. E. Characterization of Epstein-Barr virus-carrying cell lines established from chronic lymphocytic leukemia. Cancer Res. 1983 Mar;43(3):1195–1203. [PubMed] [Google Scholar]
  12. Melo J. V., Brito-Babapulle V., Foroni L., Robinson D. S., Luzzatto L., Catovsky D. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer. 1986 Oct 15;38(4):531–538. doi: 10.1002/ijc.2910380413. [DOI] [PubMed] [Google Scholar]
  13. Melo J. V., Catovsky D., Bodger M. Reactivity of the monoclonal antibody RFB1 in chronic B-cell leukaemias. Scand J Haematol. 1984 Apr;32(4):417–422. doi: 10.1111/j.1600-0609.1984.tb00698.x. [DOI] [PubMed] [Google Scholar]
  14. Melo J. V., Catovsky D., Galton D. A. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol. 1986 Jun;63(2):377–387. [PubMed] [Google Scholar]
  15. Melo J. V., Hegde U., Parreira A., Thompson I., Lampert I. A., Catovsky D. Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol. 1987 Jun;40(6):642–651. doi: 10.1136/jcp.40.6.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Melo J. V., San Miguel J. F., Moss V. E., Catovsky D. The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies. Semin Oncol. 1984 Dec;11(4):381–385. [PubMed] [Google Scholar]
  17. Miller G., Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973 Jan;70(1):190–194. doi: 10.1073/pnas.70.1.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Miyoshi I., Hiraki S., Tsubota T., Hikita T., Masuji H., Nishi Y., Kimura I. Hairy cell leukemia: establishment of a cell line and its characteristics. Cancer. 1981 Jan 1;47(1):60–65. doi: 10.1002/1097-0142(19810101)47:1<60::aid-cncr2820470112>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  19. Nilsson K., Pontén J. Classification and biological nature of established human hematopoietic cell lines. Int J Cancer. 1975 Feb 15;15(2):321–341. doi: 10.1002/ijc.2910150217. [DOI] [PubMed] [Google Scholar]
  20. Parreira A., Robinson D. S., Melo J. V., Ayliffe M., Ball S., Hegde U., Baughan A., Fairhead S., Talavera J. G., Katzmann J. A. Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases. Scand J Haematol. 1985 Nov;35(5):570–578. doi: 10.1111/j.1600-0609.1985.tb02830.x. [DOI] [PubMed] [Google Scholar]
  21. Patarroyo M., Beatty P. G., Nilsson K., Gahmberg C. G. Identification of a cell-surface glycoprotein mediating cell adhesion in EBV-immortalized normal B cells. Int J Cancer. 1986 Oct 15;38(4):539–547. doi: 10.1002/ijc.2910380414. [DOI] [PubMed] [Google Scholar]
  22. Posnett D. N., Chiorazzi N., Kunkel H. G. Monoclonal antibodies with specificity for hairy cell leukemia cells. J Clin Invest. 1982 Aug;70(2):254–261. doi: 10.1172/JCI110612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  24. Rickinson A. B., Finerty S., Epstein M. A. Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. Clin Exp Immunol. 1982 Nov;50(2):347–354. [PMC free article] [PubMed] [Google Scholar]
  25. Sairenji T., Spiro R. C., Reisert P. S., Paquin L., Sakamoto K., Shibuya A., Sullivan J. L., Katayama I., Humphreys R. E. Analysis of transformation with Epstein-Barr virus and phenotypic characteristics of lymphoblastoid cell lines established from patients with hairy cell leukemia. Am J Hematol. 1983 Dec;15(4):361–374. doi: 10.1002/ajh.2830150407. [DOI] [PubMed] [Google Scholar]
  26. Saxon A., Stevens R. H., Quan S. G., Golde D. W. Immunologic characterization of hairy cell leukemias in continuous culture. J Immunol. 1978 Mar;120(3):777–782. [PubMed] [Google Scholar]
  27. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  28. Tatsumi E., Harada S., Bechtold T., Lipscomb H., Davis J., Kuszynski C., Volsky D. J., Han T., Armitage J., Purtilo D. T. In-vitro infection of chronic lymphocytic leukemia cells by Epstein-Barr virus (EBV). Leuk Res. 1986;10(2):167–177. doi: 10.1016/0145-2126(86)90039-1. [DOI] [PubMed] [Google Scholar]
  29. Zeuthen J. Epstein-Barr virus (EBV), lymphocytes and transformation. J Cancer Res Clin Oncol. 1983;106(1):1–11. doi: 10.1007/BF00399890. [DOI] [PubMed] [Google Scholar]
  30. zur Hausen H., Bornkamm G. W., Schmidt R., Hecker E. Tumor initiators and promoters in the induction of Epstein-Barr virus. Proc Natl Acad Sci U S A. 1979 Feb;76(2):782–785. doi: 10.1073/pnas.76.2.782. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES